Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.63 |
| ▸ | TYMS | P04818 | 4/20 | 0.54 |
| ▸ | DHFR | P00374 | 3/20 | 0.54 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.49 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.46 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.46 |
| ▸ | GART | P22102 | 1/20 | 0.46 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.46 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836419 | 0.93 | NAMPT (0.56) | NAMPTTYMSDHFRMBOAT4 | |
| SCHEMBL9046718 | 0.90 | TYMS (0.54) | NAMPTTYMSDHFRMBOAT4FOLR2 | |
| SCHEMBL27684624 | 0.87 | NAMPT (0.53) | NAMPTTYMSDHFRMBOAT4 | |
| SCHEMBL27709354 | 0.86 | TYMS (0.53) | NAMPTTYMSDHFRMBOAT4FOLR2 | |
| SCHEMBL27684623 | 0.84 | NAMPT (0.48) | NAMPTTYMSDHFRMBOAT4 | |
| SCHEMBL7843188 | 0.84 | NAMPT (0.57) | NAMPTTYMSDHFR | |
| SCHEMBL9045691 | 0.83 | TYMS (0.48) | NAMPTTYMSDHFRFOLR2FOLR1 | |
| SCHEMBL27665158 | 0.83 | NAMPT (0.47) | NAMPTTYMSDHFRMBOAT4 | |
| SCHEMBL27665156 | 0.82 | NAMPT (0.46) | NAMPTTYMSDHFR | |
| SCHEMBL15247798 | 0.81 | NAMPT (0.52) | NAMPTTYMSDHFRMBOAT4FOLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | Chelsea Thereapeutics, Inc. | 2011-06-23 | — | — | US | disclosed |
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | Chelsea Thereapeutics, Inc. | 2011-06-23 | — | — | US | disclosed |
| US-7951812-B2 | For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007) | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951812-B2 | For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007) | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008089390-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-0530537-B1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-01-08 | — | — | EP | disclosed |
| US-5403843-A | Pyrrolopyrimidinyalglutaminate derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0530537-A1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | CCR9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNO | NAMPT 1072/4885TYMS 154/4885DHFR 105/4885 |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | FFAR3, CCR9, NR1H3 | NAMPT 1796/4885TYMS 1972/4885DHFR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.